CLR and its three putative peptide agonists–adrenomedullin (AM), calcitonin gene-related peptide (CGRP), and AM2/intermedin are implicated in cardiovascular and skin diseases, migraine, and cancer (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26). This evidence concerns the gene DCLK3 and cancer.